DPP4 Inhibitors Turnover is Important in Controlling Blood Glucose in Type 2 Diabetes

Abstract

We should put into consideration that some humans are genetically more susceptible to develop type 2 diabetes than others. Of them, transcription factor 7-like 2 (TCF7L2) is the gene which is more accusative. Dipeptidyl peptidase 4 Inhibitors (DPP-4 inhibitors) are considered as a comparatively new class of anti hyperglycemic drugs, the first agent of this group was approved by FDA in 2006. This group known as gliptins work in a physiological manner, as we all know ,enteroendocrine l cells in the intestine produce glucagon-like peptide-1,a hormone acting on glp1 receptors on pancreatic beta cells, leading to physiological insulin release. Dpp 4 inhibitors are classified into 3 classes according to subsite interaction in the dpp4 enzyme. Materials and methods: 200 patients of type2 diabetes mellitus followed in a private clinic for 6 months in observational prospective study. Results: The results of our study show that turnover of dpp4 inhibitors in treatment of type 2 diabetes decrease hba1c and improve treatment outcomes. Conclusion: Dpp4 inhibitors turnover in diabetes mellitus treatment give a good control of type 2 diabetes better than using on drug for a long time.